Vera Therapeutics, Inc.

NasdaqGM:VERA Stock Report

Market Cap: US$2.7b

Vera Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:VERA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
15 May 24SellUS$83,866Joseph YoungIndividual1,965US$42.68
10 Apr 24SellUS$228,560Joseph YoungIndividual5,714US$40.00
03 Apr 24SellUS$735,205Sean GrantIndividual18,649US$40.06
25 Mar 24SellUS$34,099,583Sofinnova Investment, Inc.Company834,459US$46.18
30 Jan 24BuyUS$4,999,990Sofinnova Investment, Inc.Company161,290US$31.00
10 Jan 24SellUS$18,900,000Commodore Capital LPCompany1,050,000US$18.00

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of VERA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders448,4860.708%
General Public495,9050.783%
Private Companies1,913,5013.02%
Hedge Funds4,309,5906.81%
VC/PE Firms5,144,2128.12%
Institutions51,011,35980.6%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.5%.

Top Shareholders

Top 25 shareholders own 77.72% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.12%
Longitude Capital Management Co., LLC
5,144,212US$219.1m0%44.12%
7.77%
T. Rowe Price Group, Inc.
4,923,110US$209.7m36%0.02%
6.81%
Avoro Capital Advisors LLC
4,309,590US$183.6m0%2.56%
5.45%
BlackRock, Inc.
3,452,202US$147.1m3.43%no data
4.41%
Sofinnova Investment, Inc.
2,793,987US$119.0m0%10.6%
4.4%
FMR LLC
2,785,155US$118.6m-0.59%0.01%
4.07%
The Vanguard Group, Inc.
2,580,177US$109.9m2.22%no data
3.91%
Commodore Capital LP
2,475,000US$105.4m0%7.29%
3.24%
Eversept Partners, L.P.
2,050,157US$87.3m0.34%7.31%
3.09%
Holocene Advisors, LP
1,954,528US$83.3m8.82%0.33%
3.02%
E. Merck KG
1,913,501US$81.5m0%no data
2.88%
State Street Global Advisors, Inc.
1,823,807US$77.7m-15.4%no data
2.49%
Kynam Capital Management, LP
1,576,549US$67.2m2.13%5.43%
2.17%
Adage Capital Management, L.P.
1,374,000US$58.5m22.8%0.1%
2.15%
Samlyn Capital, LLC
1,359,227US$57.9m10.3%0.93%
2.12%
Kleiner Perkins Caufield & Byers
1,343,152US$57.2m0%13.61%
1.73%
Paradigm Biocapital Advisors LP
1,096,851US$46.7m0%1.72%
1.59%
Geode Capital Management, LLC
1,004,665US$42.8m2.05%no data
1.58%
Woodline Partners LP
1,000,893US$42.6m5.48%0.37%
1.32%
Artal Group S.A.
837,928US$35.7m-8.52%1.06%
1.21%
Deutsche Asset & Wealth Management
766,544US$32.7m20.7%0.01%
1.11%
First Light Asset Management, LLC
705,234US$30.0m-29.9%2.7%
1.08%
Altium Capital Management LP
684,000US$29.1m-4.2%9.32%
1.07%
OrbiMed Advisors LLC
675,872US$28.8m0%0.41%
0.92%
Marshall Wace LLP
583,725US$24.9m11.3%0.04%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:07
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vera Therapeutics, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pete StavropoulosCantor Fitzgerald & Co.
Liisa BaykoEvercore ISI
Vamil DivanGuggenheim Securities, LLC